GSK-3 as potential target for therapeutic intervention in cancer
James A. McCubrey(East Carolina University), Melchiorre Cervello(Foundation for Biomedical Research), Massimo Libra(University of Catania), Roberta Maestro(Centro di Riferimento Oncologico), Lucio Cocco(University of Bologna), Antonino B. D’Assoro(Mayo Clinic), Alberto M. Martelli(University of Bologna), Agnieszka Gizak(University of Wrocław), Dariusz Rakus(University of Wrocław), Melissa L. Sokolosky(East Carolina University), Giuseppe Montalto(University of Palermo), Zoya N. Demidenko(Roswell Park Comprehensive Cancer Center), Ferdinando Nicoletti(University of Catania), Fred E. Bertrand(East Carolina University), Steve L. Abrams(East Carolina University), Linda S. Steelman(East Carolina University), Jörg Bäsecke(University of Göttingen)
Cited by 508
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
|Frontiers in Pharmacology|2018|878
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
twist is a potential oncogene that inhibits apoptosis
|Genes & Development|1999|508